Advertisement

Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment

  • Rebaz Ahmed
  • Narsireddy Amreddy
  • Anish Babu
  • Anupama Munshi
  • Rajagopal RameshEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)

Abstract

Recent developments in nanotechnology, especially in drug delivery systems, are advanced by featuring novel multifunctional nanoparticles that promise safe, specific, and efficient therapeutic delivery for cancer treatment. Multifunctional nanoparticle-based drug delivery systems enable simultaneous delivery of multiple therapeutic agents for effective combination therapy for cancer. In this chapter, we provide detailed protocols for development and application of a multifunctional nanoparticle system for combinatorial delivery of a chemotherapeutic (cisplatin) and small interfering RNA (siRNA) for human antigen R (HuR) mRNA in cancer cells using a polyamidoamine (PAMAM) dendrimer platform. Protocols for nanoparticle functionalization with folic acid (FA) for targeted delivery of therapeutics toward folate receptor (FR)-overexpressing cancer cells are also described. Further, methods employed for physiochemical and functional characterization of the multifunctional nanoparticle system are discussed in detail. Using the methods described in this chapter, researchers would be able to develop PAMAM dendrimer-based multifunctional nanoparticles for targeted delivery of chemotherapeutics and siRNA combinations. We also provide an example showing the dendrimer-polyethyleneimine-cis-diamminedichloroplatinum-siRNA-folic acid (Den-PEI-CDDP-siRNA-FA) nanoparticle system developed was therapeutically effective toward non-small cell lung cancer (NSCLC) cell lines (H1299 and A549) while exhibiting reduced toxicity to normal lung fibroblast (MRC9) cells.

Keywords

PAMAM dendrimers CDDP HuR siRNA Lung cancer Folic acid 

Notes

Acknowledgments

The work was supported in part by a grant received from the National Institutes of Health (NIH), R01 CA167516 (RR), an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences (P20 GM103639) of the National Institutes of Health (RR & AM), VA MERIT grant 101B × 003420 (RR) and by funds received from the Stephenson Cancer Center Seed Grant (RR), Presbyterian Health Foundation Seed Grant (RR), Presbyterian Health Foundation Bridge Grant (RR), and Jim and Christy Everest Endowed Chair in Cancer Developmental Therapeutics (RR) at the University of Oklahoma Health Sciences Center. Rajagopal Ramesh is an Oklahoma TSET Research Scholar and holds the Jim and Christy Everest Endowed Chair in Cancer Developmental Therapeutics. The authors thank Ms. Kathy Kyler at the office of Vice President for Research, OUHSC, for editorial assistance.

References

  1. 1.
    Ma L, Kohli M, Smith A (2013) Nanoparticles for combination drug therapy. ACS Nano 7:9518–9525.  https://doi.org/10.1021/nn405674mCrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sonawane R, Harde H, Katariya M et al (2014) Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin Drug Deliv 11:1833–1847.  https://doi.org/10.1517/17425247.2014.938634CrossRefPubMedGoogle Scholar
  3. 3.
    Cao P, Bae Y (2012) Polymer nanoparticulate drug delivery and combination cancer therapy. Future Oncol 8:1471–1480.  https://doi.org/10.2217/fon.12.139CrossRefPubMedGoogle Scholar
  4. 4.
    Kydd J, Jadia R, Velpurisiva P et al (2017) Targeting strategies for the combination treatment of cancer using drug delivery systems. Pharmaceutics 9:46.  https://doi.org/10.3390/pharmaceutics9040046CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Narsireddy A, Vijayashree K, Adimoolam MG et al (2015) Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy. Int J Nanomedicine 10:6865–6878.  https://doi.org/10.2147/IJN.S89474CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Navath RS, Menjoge AR, Wang B et al (2010) Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications. Biomacromolecules 11:1544–1563.  https://doi.org/10.1021/bm100186bCrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tekade RK, Kumar PV, Jain NK (2009) Dendrimers in oncology: an expanding horizon. Chem Rev 109:49–87.  https://doi.org/10.1021/cr068212nCrossRefPubMedGoogle Scholar
  8. 8.
    Xu Z, Kahr M, Walker KL et al (1994) Phenylacetylene dendrimers by the divergent, convergent, and double-stage convergent methods. J Am Chem Soc 116:4537–4550.  https://doi.org/10.1021/ja00090a002CrossRefGoogle Scholar
  9. 9.
    Grayson SM, Fréchet JM (2001) Convergent dendrons and dendrimers: from synthesis to applications. Chem Rev 101:3819–3868.  https://doi.org/10.1021/cr990116hCrossRefPubMedGoogle Scholar
  10. 10.
    Madaan K, Kumar S, Poonia N et al (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 6:139–150.  https://doi.org/10.4103/0975-7406.130965CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dufès C, Uchegbu IF, Schätzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57:2177–2202.  https://doi.org/10.1016/j.addr.2005.09.017CrossRefPubMedGoogle Scholar
  12. 12.
    Amreddy N, Babu A, Panneerselvam J et al (2017) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373–384.  https://doi.org/10.1016/j.nano.2017.11.010CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Rebaz Ahmed
    • 1
    • 2
  • Narsireddy Amreddy
    • 1
    • 3
  • Anish Babu
    • 1
    • 3
  • Anupama Munshi
    • 3
    • 4
  • Rajagopal Ramesh
    • 1
    • 2
    • 3
    • 5
    Email author
  1. 1.Department of PathologyThe University of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Graduate Program in Biomedical SciencesThe University of Oklahoma Health Sciences CenterOklahoma CityUSA
  3. 3.Stephenson Cancer CenterThe University of Oklahoma Health Sciences CenterOklahoma CityUSA
  4. 4.Department of Radiation OncologyThe University of Oklahoma Health Sciences CenterOklahoma CityUSA
  5. 5.Stanton L. Young Biomedical Research CenterThe University of Oklahoma Health Sciences CenterOklahoma CityUSA

Personalised recommendations